147
Participants
Start Date
November 4, 2015
Primary Completion Date
November 26, 2019
Study Completion Date
January 18, 2021
Anifrolumab
Administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112
Placebo
Administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112
Research Site, Taipei
Research Site, Taoyuan
Research Site, Brussels
Research Site, Budapest
Research Site, Belgrade
Research Site, Brussels
Research Site, Westmead
Research Site, Leuven
Research Site, Parkville
Research Site, Debrecen
Research Site, Adelaide
Research Site, Córdoba
Research Site, Szeged
Research Site, Kaposvár
Research Site, New York
Research Site, New York
Research Site, Berlin
Research Site, The Bronx
Research Site, Belgrade
Research Site, Great Neck
Research Site, New Hyde Park
Research Site, Marseille
Research Site, México
Research Site, Suwon
Research Site, Niš
Research Site, Milan
Research Site, Novi Sad
Research Site, Kiel
Research Site, Chihuahua City
Research Site, Toulouse
Research Site, DeBary
Research Site, Bordeaux
Research Site, Padua
Research Site, Memphis
Research Site, Taichung
Research Site, Taichung
Research Site, Reggio Emilia
Research Site, Columbus
Research Site, Guadalajara
Research Site, Guadalajara
Research Site, Changhua
Research Site, Pisa
Research Site, Strasbourg
Research Site, Oklahoma City
Research Site, Paris
Research Site, San Luis Potosí City
Research Site, Aurora
Research Site, Kaohsiung City
Research Site, Phoenix
Research Site, Glendale
Research Site, Thousand Oaks
Research Site, Saint Petersburg
Research Site, Saint Petersburg
Research Site, Orenburg
Research Site, La Jolla
Research Site, Los Angeles
Research Site, Boston
Research Site, Newark
Research Site, Buenos Aires
Research Site, Rosario
Research Site, Clayton
Research Site, Liège
Research Site, Arequipa
Research Site, Lima
Research Site, Lima
Research Site, Lima
Research Site, Lima
Research Site, Lima
Research Site, Lima
Research Site, Lima
Research Site, Lima
Research Site, Krakow
Research Site, Lodz
Research Site, Warsaw
Research Site, Gwangju
Research Site, Seoul
Research Site, Seoul
Research Site, Barcelona
Research Site, Barcelona
Research Site, London
Lead Sponsor
Collaborators (1)
Parexel
INDUSTRY
AstraZeneca
INDUSTRY